The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Bharat Biotech expects to share further details of the trial results as additional data become available.
The price increases are due to the rising costs of raw materials.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
PEL will explore the PLI scheme and apply if its beneficial.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
Subscribe To Our Newsletter & Stay Updated
